AstraZeneca Sees 27% Q2 Profit Surge Driven by Record US Market Growth

British pharmaceutical major AstraZeneca announced on Tuesday a 27% rise in net profit for the second quarter of the year, buoyed by exceptional performance in the United States — its key growth market.

According to the company’s Q2 earnings statement, profit after tax reached $2.45 billion for the three months ending 30 June, a significant increase from the same period last year.

This surge follows AstraZeneca’s recent multi-billion-dollar investment in the US, which appears to be paying dividends through heightened market penetration and revenue gains.

The pharmaceutical firm, headquartered in Cambridge, has recently doubled down on its American footprint, aiming to secure a larger share in one of the world’s most competitive and lucrative healthcare markets.

The second-quarter figures reflect strong product performance, increased demand across therapeutic areas, and a robust sales trajectory in the US — now a central pillar of AstraZeneca’s global strategy. Further detailed financial disclosures and revenue breakdowns across divisions are expected in the company’s forthcoming full financial report.